Many clinical trials for advanced breast cancer require that patients have a measurable lesion. The criteria doctors use to determine which lesions should be measured and how they are measured is called RECIST (Response Evaluation Criteria in Solid Tumors).
To help you understand these criteria, below you will find links to information about RECIST and its criteria for addressing metastatic lesions, bone only metastases and response to immunotherapy treatments.
- Nature: Bone Only Mets: Measurable?
- What is RECIST?
- Official Site of RECIST Working Group
- iRECIST: the RECIST for Immunotherapy Clinical Trials
- Alliance for Clinical Trials in Oncology: The Purpose of RECIST Guidelines (PDF)
